10:20 AM EST - Aeterna Zentaris Inc. : presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer. Aeterna Zentaris Inc.
shares T.AEZ are trading up $0.06 at $1.96.
